Trial intelligence / Profile preview

TIGER-2: CO-1686 as second-line EGFR-directed TKI in EGFR-mutant NSCLC

2013-005532-23Phase 2Completed

Sponsor

Clovis Oncology

Start

Apr 2014

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1